PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Confers Enabling Technology Award on Peptisyntha - Optimal peptide purity, quality yield, development timeline and affordable pricing are hallmarks of company’s success in therapeutic peptides market - Peptisyntha.com
Frost & Sullivan Confers Enabling Technology Award on Peptisyntha

 

NewswireToday - /newswire/ - Brussels, Belgium, 2011/12/12 - Optimal peptide purity, quality yield, development timeline and affordable pricing are hallmarks of company’s success in therapeutic peptides market - Peptisyntha.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the therapeutic peptides market, Frost & Sullivan recognises Peptisyntha with the 2011 Europe Frost & Sullivan Award for Enabling Technology. Continued research of potentially cost-effective and novel applications of technologies for peptide production is indicative of Peptisyntha’s ever-expanding competencies.

“Peptisyntha is one of the few suppliers that can provide high quality, cGMP-compliant therapeutic peptide products and services at competitive prices to customers in the pharmaceutical and biotechnology industries,” notes Frost & Sullivan Research Analyst Aiswariya Chidambaram. “A versatile and innovative technology portfolio has enabled Peptisyntha to implement various synthesis processes, customised to suit customer-specific needs.”

Key technologies include Silylation technology used in peptide synthesis, Tetraphenylborate (TBP) technology for the synthesis of Arginine-rich peptides, world class manufacturing processes of non-natural amino acid building blocks and others such as the use of Phenyl-oxy-carbonyl-protection (Phoc-AA) of amino acids/ peptides in the coupling reaction.

Silylation technology enables working with non-protected amino acids and peptide fragments, thereby reducing the need for protection and de-protection steps. This, in turn, translates into saving of labour, resources and cost as well as optimal equipment utilisation.

Tetraphenylborate technology aids the cost-effective manufacturing of Arginine- and Lysine-rich peptides, such as anti-microbial peptides and cell penetrating peptides. The LHRH or GnRH peptides produced using Peptisyntha’s exclusive TPB technology, are a well-known class of therapeutic peptides manufactured cost effectively by Peptisyntha. These peptides find use in several therapeutic domains, including the treatment of hormone-dependent cancers and fertility control.

“Peptisyntha’s proprietary technologies enable cost-effective production of APIs by increasing yield and purity, reducing the number of chemical steps, avoiding racemisation” remarks Aiswariya Chidambaram. “The technologies offered by Peptisyntha are highly flexible, as they are not limited to one typical product line, but can be used for a wide range of peptide APIs spanning all therapeutic areas.”

Currently, the company is working on two projects based on advanced peptide biomaterials using peptide self-assembling properties. Firstly, peptide hydrogels for cell culture and, secondly, peptide-based biomaterials for sustained/controlled drug release.

“With peptide-dedicated laboratories, kilo labs, pilot and commercial scale manufacturing units, Peptisyntha offers the advantage of a single point of contact for R&D, process development and production of peptide APIs,” concludes Aiswariya Chidambaram. “The company has excelled in delivering its technology to market participants by ensuring optimal peptide purity, quality yield, development timeline and affordable pricing” Said Dr. Johan Devenyns, Managing Director of Solvay Peptides. “This Award is the result of more than two decades of efforts and innovation to contribute to our customers’ success around the globe. Performance and expertise combined with innovative solutions lead to this competitive advantage our customers are benefitting from” added Dr. Mimoun Ayoub, Vice President Global Business & Strategic Developments.

The Enabling Technology Award is presented to the company that has demonstrated success in enabling the creation of new products, enhancing current products and enabling new applications. Other criteria according to which the company was selected as the award recipient include potential for market acceptance and breadth of access to technology.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Peptisyntha

Peptisyntha (peptisyntha.com) is a leading cGMP manufacturer of therapeutic peptides (peptide APIs) and peptidomimetics serving customers from the pharmaceutical, biotech, diagnostic and cosmetic industries.

With 25 years of experience in peptide manufacturing Peptisyntha provides a seamless portfolio of expertise from lead optimization to commercial cGMP manufacturing. With two GMP manufacturing facilities in USA and Belgium, Peptisyntha masters all manufacturing technologies (SPPS, LPPS and hybrid approaches) at all scales Peptisyntha is a wholly owned company of Solvay, an international chemical group active in chemistries contributing to improving quality of life.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Confers Enabling Technology Award on Peptisyntha

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Peptisyntha | Frost & Sullivan
Publisher Contact: Catherine Brassell - Frost.com 
+27(0)21 680 3267 catherine.brassell[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)